Antimicrobial activity of latamoxef (moxalactam) against both Bacteroides fragilis and Escherichia coli in an intraperitoneal abscess model.
The antimicrobial activity of latamoxef (moxalactam) was examined against Bacteroides fragilis and Escherichia coli individually and in combination in an intraperitoneal tissue capsule animal model during ten days of therapy given at 40 mg/kg/day. Mean peak serum concentration was 32.8 mg/l. Mean capsular latamoxef concentrations during samplings on days three, seven and ten were 1.8 mg/l for Bact. fragilis, 0.7 mg/l for E. coli, less than 0.5 mg/l for polymicrobial infection and 3.4 mg/l in uninoculated controls. Capsular colony counts for Bact. fragilis and E. coli monomicrobial infections decreased by 2.2 and 4.0 log10 cfu respectively and 1.9 and 3.6 log10 cfu in polymicrobial infections. Latamoxef concentrations necessary to eliminate viable bacteria in both monomicrobial and polymicrobial capsules were not achieved.
D000038:Abscess / Q000188:drug therapy*; D000818:Animals; D001202:Ascitic Fluid / Q000378:metabolism; D001442:Bacteroides Infections / Q000188:drug therapy*; D001441:Bacteroides fragilis; D004927:Escherichia coli Infections / Q000188:drug therapy*; D009070:Moxalactam / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D010532:Peritoneal Diseases / Q000188:drug therapy*; D011817:Rabbits
D009070:Moxalactam